Injective Price Stalled as Whales Bet on Upside

Injective (INJ) is trading at $7.52, showing little momentum and facing strong sell-side pressure. Despite this, top traders are positioning themselves 58.6% long, suggesting a divide between smart money and retail sentiment. The token has been stuck in a tight range between $7.36 and $7.71, with a 0.78% decline over 24 hours. The internal market dynamics indicate sellers are dominating the short-term action, putting the onus on buyers to prove their strength.

The technical outlook for INJ is mixed. The MACD histogram is flat, indicating stalled momentum, while the Stochastic oscillator is deeply oversold at 24.87/%K against 19.90/%D. The RSI remains at a healthy 57.95, suggesting short-term pain without a breakdown in broader momentum. The moving average stack is bullish, with INJ trading above its SMA 20, SMA 50, and SMA 200, confirming a strong medium-to-long-term trend. However, the narrowing spread between the EMA 12 and EMA 26 has contributed to the flat MACD.

Whale accumulation is contrasting with retail selling. Top traders are heavily long at a 1.42 ratio, but the taker buy/sell ratio at 0.68 shows aggressive sellers are winning the short-term battle. Open interest has risen by 3.23% to nearly $30 million notional, signaling new shorts or long positions being built against a headwind. The funding rate remains neutral at 0.0100%, reducing the likelihood of a violent short squeeze.

Looking ahead, INJ has two potential paths. The bullish scenario (55% probability) involves holding the $7.35 support, reclaiming $7.70 resistance, and targeting $8.85. The bearish scenario (45% probability) sees a break below $7.35, leading to a drop toward $6.05. A weekly close below $6.85 would invalidate the bullish thesis, while a move above $8.00 would shift the focus to higher resistance levels.